Target Name: TIMP1
NCBI ID: G7076
Review Report on TIMP1 Target / Biomarker Content of Review Report on TIMP1 Target / Biomarker
TIMP1
Other Name(s): TIMP1_HUMAN | CLGI | Erythroid potentiating activity | EPO | Erythroid-potentiating activity | epididymis secretory sperm binding protein | TIMP | Fibroblast collagenase inhibitor | Metalloproteinase inhibitor 1 | HCI | Tissue inhibitor of metalloproteinases 1 | erythroid potentiating activity | Collagenase inhibitor | tissue inhibitor of metalloproteinases 1 | TIMP metallopeptidase inhibitor 1 | EPA | collagenase inhibitor | TIMP-1 | fibroblast collagenase inhibitor

Introduction to TIMP1, A Potential Drug Target

Drug targets and biomarkers play a crucial role in the field of medicine and pharmaceutical research. They serve as key indicators for disease diagnosis, prognosis, and potential therapeutic interventions. One such biomarker is TIMP1 (Tissue Inhibitor of Metalloproteinase 1), which has garnered significant attention in recent years due to its association with various diseases and its potential as a drug target. In this article, we will explore the diverse roles of TIMP1 and its significance as a drug target.

What is TIMP1?

TIMP1 is a protein that belongs to the family of tissue inhibitors of metalloproteinases (TIMPs). It is primarily involved in inhibiting matrix metalloproteinases (MMPs) - a group of enzymes responsible for the breakdown of the extracellular matrix (ECM) components such as collagen and elastin. TIMP1 binds to active MMPs, forming stable complexes and preventing their proteolytic activity.

Role of TIMP1 in Disease

1. Cancer: Several studies have linked TIMP1 to cancer progression and metastasis. High expression of TIMP1 has been observed in various cancers, including breast, ovarian, lung, and colorectal cancer. Its overexpression is often associated with poor prognosis and aggressive tumor behavior. Researchers suggest that TIMP1 promotes tumor growth by aiding angiogenesis (formation of new blood vessels) and suppressing the immune system's response to cancer cells.

2. Fibrosis: Fibrosis is a condition characterized by excessive deposition of ECM components, leading to tissue scarring and organ dysfunction. TIMP1 plays a prominent role in this process by inhibiting the activity of ECM-degrading enzymes, primarily MMPs. However, excessive TIMP1 expression can disrupt the balance between ECM deposition and degradation, leading to progressive fibrosis. Thus, TIMP1 becomes a potential target for developing antifibrotic therapies.

3. Cardiovascular Diseases: Studies have demonstrated the involvement of TIMP1 in various cardiovascular conditions, including atherosclerosis, myocardial infarction, and heart failure. TIMP1 levels are elevated in these diseases, leading to increased ECM remodeling and plaque instability. Targeting TIMP1 could potentially inhibit the excessive ECM remodeling observed in cardiovascular diseases and reduce the associated risks.

TIMP1 as a Drug Target

Given the significant role of TIMP1 in various diseases, it has emerged as a promising drug target. Developing drugs that selectively modulate TIMP1 levels or its interaction with MMPs could offer new therapeutic opportunities. Several strategies are being explored to target TIMP1 effectively:

1. Small Molecule Inhibitors: Designing small molecules that specifically bind to TIMP1 and prevent its interaction with MMPs is a potential approach. Such inhibitors could disrupt the TIMP1-MMP complex and restore normal ECM remodeling processes.

2. RNA Interference (RNAi): Utilizing RNAi technology, specific parts of the TIMP1 gene can be targeted to reduce its expression. By doing so, the overactivity of TIMP1 in disease states could be controlled, contributing to better patient outcomes.

3. Monoclonal Antibodies: Monoclonal antibodies against TIMP1 can be developed to inhibit its activity or interfere with its interaction with MMPs. These antibodies can be engineered to selectively bind to TIMP1 and interfere with its pathological functions.

Clinical Applications and Challenges

Harnessing TIMP1 as a drug target holds promise in various clinical applications. In cancer, therapies targeting TIMP1 could complement existing treatments and improve patient outcomes, especially in aggressive tumor types where TIMP1 expression is elevated. In fibrosis, inhibiting TIMP1 activity could prevent excessive ECM deposition and halt disease progression.

However, there are challenges to overcome. First, achieving target specificity is crucial to avoid any unintended consequences while manipulating TIMP1 levels. Second, identifying optimal dosing strategies and drug formulations is necessary to ensure effective and safe administration. Lastly, validating the clinical benefits of targeting TIMP1 requires extensive research and clinical trials.

Conclusion

TIMP1 plays a multifaceted role in various diseases, making it an attractive biomarker and drug target. Its involvement in cancer progression, fibrosis, and cardiovascular diseases highlights its potential for the development of targeted therapies. While there are challenges to address, ongoing research aims to harness TIMP1's potential to improve patient outcomes and advance the field of precision medicine.

Protein Name: TIMP Metallopeptidase Inhibitor 1

Functions: Metalloproteinase inhibitor that functions by forming one to one complexes with target metalloproteinases, such as collagenases, and irreversibly inactivates them by binding to their catalytic zinc cofactor. Acts on MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13 and MMP16. Does not act on MMP14. Also functions as a growth factor that regulates cell differentiation, migration and cell death and activates cellular signaling cascades via CD63 and ITGB1. Plays a role in integrin signaling. Mediates erythropoiesis in vitro; but, unlike IL3, it is species-specific, stimulating the growth and differentiation of only human and murine erythroid progenitors

The "TIMP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIMP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TIMP2 | TIMP3 | TIMP4 | TINAG | TINAGL1 | TINCR | TINF2 | TIPARP | TIPARP-AS1 | TIPIN | TIPRL | TIRAP | TIRAP-AS1 | TJAP1 | TJP1 | TJP2 | TJP3 | TK1 | TK2 | TKFC | TKT | TKTL1 | TKTL2 | TLCD1 | TLCD2 | TLCD3A | TLCD3B | TLCD4 | TLCD4-RWDD3 | TLCD5 | TLDC2 | TLE1 | TLE1-DT | TLE2 | TLE3 | TLE4 | TLE5 | TLE6 | TLK1 | TLK2 | TLL1 | TLL2 | TLN1 | TLN2 | TLNRD1 | TLR1 | TLR10 | TLR12P | TLR2 | TLR3 | TLR4 | TLR5 | TLR6 | TLR7 | TLR8 | TLR8-AS1 | TLR9 | TLX1 | TLX1NB | TLX2 | TLX3 | TM2D1 | TM2D2 | TM2D3 | TM4SF1 | TM4SF1-AS1 | TM4SF18 | TM4SF19 | TM4SF19-AS1 | TM4SF19-DYNLT2B | TM4SF20 | TM4SF4 | TM4SF5 | TM6SF1 | TM6SF2 | TM7SF2 | TM7SF3 | TM9SF1 | TM9SF2 | TM9SF3 | TM9SF4 | TMA16 | TMA7 | TMBIM1 | TMBIM4 | TMBIM6 | TMC1 | TMC2 | TMC3 | TMC4 | TMC5 | TMC6 | TMC7 | TMC8 | TMCC1 | TMCC1-DT | TMCC2 | TMCC3 | TMCO1 | TMCO1-AS1